SCHEMBL20360438

SCHEMBL20360438

O=C(CC(=O)C(F)(F)F)c1ccc(Cl)cc1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 2/20 0.44
FLT4 P35916 2/20 0.44
KDR P35968 2/20 0.44
ERCC5 P28715 3/20 0.43
FEN1 P39748 3/20 0.43
PLOD2 O00469 3/20 0.42
PLOD3 O60568 2/20 0.41
PLOD1 Q02809 2/20 0.41
MAPK1 P28482 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HIF1A Q16665 1/20 0.40
MAPT P10636 3/20 0.39
KDM4E B2RXH2 1/20 0.39
TMPRSS4 Q9NRS4 3/20 0.39
P2RX1 P51575 2/20 0.37
HPGD P15428 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
GPR27 Q9NS67 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1924137 0.84 ERCC5 (0.61) FLT1FLT4KDRERCC5FEN1
SCHEMBL31678938 0.78 FLT1 (0.46) FLT1FLT4KDRMAPK1ALDH1A1
SCHEMBL612265 0.78 FLT1 (0.46) FLT1FLT4KDRMAPK1ALDH1A1
SCHEMBL30702134 0.76 GSK3B (0.52) FLT1FLT4KDRERCC5FEN1
SCHEMBL7779200 0.76 GSK3B (0.52) FLT1FLT4KDRERCC5FEN1
SCHEMBL2870299 0.75 ALDH1A1 (0.49) FLT1FLT4KDRERCC5FEN1
SCHEMBL29444021 0.75 ALDH1A1 (0.49) FLT1FLT4KDRERCC5FEN1
SCHEMBL20364210 0.75 FLT1 (0.46) FLT1FLT4KDRERCC5FEN1
SCHEMBL7554528 0.74 FLT1 (0.43) FLT1FLT4KDRERCC5FEN1
SCHEMBL20360003 0.74 FLT1 (0.50) FLT1FLT4KDRALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282748-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2025-09-11 US disclosed
US-20230024752-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
US-11180471-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-11-23 US disclosed
CN-113292539-A Substituted oxopyridine derivatives 拜耳制药股份公司 2021-08-24 CN disclosed
CN-108026072-B Substituted oxopyridine derivatives 拜耳制药股份公司 2021-08-17 CN disclosed
EP-3319956-B1 SUBSTITUTED OXOPYRIDINE DERIVATIVES Bayer Pharma AG (DE) 2021-01-06 EP disclosed
US-10421742-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-09-24 US disclosed
US-20180194745-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10421742-B2 Substituted oxopyridine derivatives OGFOD1, VASP, PNPO FLT1 103/4885FLT4 104/4885KDR 79/4885
US-11180471-B2 Substituted oxopyridine derivatives OGFOD1, VASP, PNPO FLT1 103/4885FLT4 104/4885KDR 79/4885
US-20180194745-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES OGFOD1, VASP, PNPO FLT1 103/4885FLT4 104/4885KDR 79/4885
US-20250282748-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES OGFOD1, VASP, PNPO FLT1 103/4885FLT4 104/4885KDR 79/4885
US-20230024752-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES OGFOD1, VASP, PNPO FLT1 103/4885FLT4 104/4885KDR 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.